Cell line | CD38a | CD56a | CD138a | PC-1/CD203aa | OTRb |
|---|
DL06c | + | − | +/− | − | + |
LP-1d | ++ | − | + | − | + |
JJN3e | + | − | + | − | ++ |
U266e | − | − | + | − | +/− |
OPM-2e | + | + | + | +/− | + |
IM9e | +/− | − | ± | − | + |
NCI-H929e | ++ | +/− | +/− | − | + |
- ++, High intensity; +, medium intensity; −, no staining; +/−, low to nil staining.
- aCD38, CD56 and CD138 were selected as accepted markers of myeloma transformation.
- bPC-1/CD203a and OTR (oxytocin receptor) were included as original observations of the lab (A Chillemi, G Zaccarello, V Quarona, Mirca Lazzaretti, Eugenia Martella, Nicola Giuliani, Riccardo Ferracini, Vito Pistoia, AL Horenstein and F Malavasi, unpublished data) (67).
- cDL06 was stabilized from cells obtained from a pleural effusion of an aggressive, therapy-refractory plasma cell leukemia patient. These cells maintain a high secretion in vitro of the monoclonal protein seen in patient blood (namely, IgAλ).
- dLP-1 cell line was produced in collaboration with the lab of L Pegoraro (University of Torino) (66).
- eJJN3, U266, OPM-2, IM9 and NCI-H929 cell lines were obtained from ATCC (Manassas, VA, USA).
